Screener
Zevra Therapeutics, Inc. ZVRA Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001434647-26-000068
FAQ
- What is Zevra Therapeutics, Inc.'s total equity?
- Zevra Therapeutics, Inc. (ZVRA) reported total equity of $217.65M in Q2 2026.
- How has Zevra Therapeutics, Inc.'s total equity changed year-over-year?
- Zevra Therapeutics, Inc.'s total equity increased by 85.7% year-over-year, from $117.23M to $217.65M.
- What is the long-term trend for Zevra Therapeutics, Inc.'s total equity?
- Over 5 years (2020 to 2025), Zevra Therapeutics, Inc.'s total equity has grown at a 18.4% compound annual growth rate (CAGR), from -$66.41M to $154.66M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Zevra Therapeutics, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude